Keros Therapeutics, Inc. (KROS) Tops Q3 EPS by 2c

Keros Therapeutics, Inc. (NASDAQ: KROS) reported Q3 EPS of ($1.33), $0.02 better than the analyst estimate of ($1.35). Revenue for the quarter came in at $8 thousand.

For earnings history and earnings-related data on Keros Therapeutics, Inc. (KROS) click here.

You May Also Be Interested In

• EU proposes to curb Airbnb and short-term rentals amid housing shortage
• Computacenter Plc. (CCC:LN) PT Raised to GBP60 at JPMorgan
• ICICI Bank (ICICIBC:IN) (IBN) PT Raised to INR2,000 at Goldman Sachs